73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study.
Saved in:
| Title: | 73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. |
|---|---|
| Authors: | He, A R1 (AUTHOR), Weiss, G J2 (AUTHOR), Falchook, G3 (AUTHOR), Yee, N S4 (AUTHOR), Gil-Martin, M5 (AUTHOR), Shahda, S6 (AUTHOR), Moreno, V7 (AUTHOR), Brana, I8 (AUTHOR), Crittenden, M9 (AUTHOR), Formenti, S10 (AUTHOR), Al-Rajabi, R11 (AUTHOR), Papadopoulos, K P12 (AUTHOR), Pishvaian, M J1 (AUTHOR), Stankevich, E13 (AUTHOR), Feng, M13 (AUTHOR), Li, J14 (AUTHOR), Mathias, M15 (AUTHOR), Kroog, G15 (AUTHOR), Lowy, I15 (AUTHOR), Fury, M G15 (AUTHOR) |
| Source: | Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdy487.004 |
